While everyone gears up for one of the busiest travel times of the year, the Alzheimer’s Foundation of America is offering ...

Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...